Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Medical College of Wisconsin
Celgene
Takeda
Medical College of Wisconsin
Medical College of Wisconsin
Pfizer
Seagen Inc.
National Heart, Lung, and Blood Institute (NHLBI)
Masonic Cancer Center, University of Minnesota
Sierra Oncology LLC - a GSK company
National Heart, Lung, and Blood Institute (NHLBI)
Stanford University
Novartis
M.D. Anderson Cancer Center
Gilead Sciences
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Sunesis Pharmaceuticals
Beth Israel Deaconess Medical Center
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
M.D. Anderson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)
Seagen Inc.
M.D. Anderson Cancer Center
Seagen Inc.
Seagen Inc.
Emory University
Scios, Inc.
Mashhad University of Medical Sciences
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Chroma Therapeutics